** Shares of CSL CSL.AX fall as much as 6.7% to A$229.2, their lowest level since Oct. 30, 2023
** Shares trim some losses to last trade 4.6% lower
** Biotech giant bears the brunt of U.S. plans to announce a "major" tariff on pharmaceutical imports
** U.S. President Donald Trump said the tariff will incentivize drug companies to move their operations to the U.S.
** Health stocks .AXHJ are down 2.3%, while the broader ASX 200 index .AXJO falls 1.2%
** CSL has lost 12.7% YTD, including the day's move
(Reporting by Rajasik Mukherjee in Bengaluru)
((Rajasik.Mukherjee@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.